Rituximab use in the treatment of children with nephrotic syndrome

Background. High recurrence rates of nephrotic syndrome in children and consequences the form steroid dependence a high risk side effects from corticosteroids as result involve immunosuppressive steroid-preserving agents that would increase long-term remission. Rituximab, chimeric anti-CD20 monoclonal antibody inhibits CD20-mediated B-cell proliferation differentiation, has been identified possible alternative treatment. The purpose study — to estimate efficacy safety treatment using rituximab like we did it on three clinical cases. Materials methods. experience was analyzed according databases Scopus, Web Science, MedLine, Cochrane Library, EMBASE, Global Health our own with steroid-sensitive presented. Results. Treatment who are 5 7 years conducted. One child had second recurrence, two first recurrence. previous episode all treated recommendations KDIGO 2021. All patients received (two intravenous injections weeks apart) at dose 15 mg/kg for 5–6 hours prior administration methylprednisolone 7–10 mg/kg. hypotension 70/40 tachycardia 116–118. Reducing speed helped eliminate effects. next injection endured well. other no both injections. Moreover after 1 month without or hematological changes. is scheduled 6 months last control CD20 level. Conclusions. In general review studies confirms medication requirement evaluation. Rituximab can be considered first-line syndrome, including resource-limited settings. Our recurrent revealed slight short-term